Top Stories
The decision came after the SMARCA2 inhibitor FHD-909 (LY4050784) failed to produce the necessary efficacy in a Phase I study.
Findings from the Phase III SYNCHRONIZE-2 trial of the glucagon/GLP-1 dual agonist survodutide sent shares in Zealand Pharma down more than 10%.
The deal, which builds on the success of Dupixent (dupilumab), also includes up to $7 billion in future milestone payments.
The initiative aims to develop adaptive trial platforms using computational models, shared infrastructure and automated operations.
The experimental trispecific antibody tilrekimig entered Phase III testing a few weeks ago.
Conference News
- First disclosure of efficacy data from Phase 2/3 ANDECAL study of andecaliximab for the treatment of fibrodysplasia ossificans progressiva (FOP) -BURLINGAME, Calif.--(BUSINESS WIRE)-- āshibio, a pri...
LGSOC is a biologically distinct variant of ovarian cancer, with limited treatment options, that is generally less responsive to conventional chemotherapyResults presented in a late-breaking plenary s...
MDS-UPDRS motor scores demonstrated stability to baseline recorded at study entry with no disease progression among the 12 evaluable participants who completed 12 months of daily oral administration o...
BOSTON, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Vima Therapeutics, a clinical-stage biotechnology company focused on oral therapies for movement disorders, today announced that four poster presentations wil...
Oral presentation will highlight previously reported data demonstrating early stabilization or improvement in mFARS scores among LX2006-treated participants compared with propensity-matched control co...
